Ovarian SPORE Grand Rounds

The Dana-Farber/Harvard Cancer Center Ovarian SPORE Grand Rounds offers a multidisciplinary HMS CME conference open to DF/HCC institutions (BWH, BIDMC, BCH, HSPH, HMS and MGH). The series offers remote participation through ZoomThe series hosts renowned local, national and international speakers presenting impactful findings in ovarian cancer. Note: there will be no recordings for these talks, and all talks begin at 3PM EST, unless mentioned otherwise. 

There are currently no upcoming talks. Please check this page again later. 


June 17 - Salt Induced Kinase 2 (SIK2) as a Target for Enhancing Response to Paclitaxel and PARP Inhibitors in Ovarian and Triple Negative Breast Cancers

  • Robert C Bast Jr, MD

    MD Anderson Cancer Center

Dr. Bast is Vice President for Translational Research at The University of Texas MD Anderson Cancer Center where he holds the Harry Carothers Wiess Distinguished University Chair for Cancer Research. His office facilitates translation of new strategies, drugs and devices from the laboratory to the clinic, as well as the movement of human material and data from the clinic to laboratory. He received his education at Wesleyan University, Harvard Medical School, Johns Hopkins Hospital, the National Cancer Institute, Peter Bent Brigham Hospital and Dana-Farber Cancer Institute. Before joining the MD Anderson faculty in 1994 he served on the faculties of Harvard Medical School and Duke University Medical Center where he was Director of the Duke Comprehensive Cancer Center. [Read More]


May 20 - New Insights on Mechanisms of IDO-mediated Immune Suppression in Ovarian Cancer

  • Adekunle "Kunle" Odunsi, MD, PhD, FRCOG, FACOG

    University of Chicago Medicine Comprehensive Cancer Center

Dr. Odunsi is a gynecologic oncologist whose research focuses on understanding the mechanisms of immune recognition and tolerance in ovarian cancer and translating these findings to immunotherapy clinical trials. He pioneered the development of antigen-specific vaccine therapy and “next generation” adoptive T-cell immunotherapies to prolong remission rates in women with ovarian cancer. [Read More]


April 15 - Rare Ovarian Cancers: Manifestations of Specific Cell Context, Mutation, and Microenvironment Interactions

  • David Huntsman, MD, FRCPC, FCCMG, FRSC, FCAHS

    BC Cancer Research Centre

Dr. David Huntsman (MD, FRCPC, FCCMG) is the Dr. Chew Wei Memorial Professor of Gynaecologc Oncology, holds the Canada Research Chair (Tier 1) in Molecular and Genomic Pathology, and is a Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at UBC. He is also the co-Founder and Director of OVCARE, BC's multidisciplinary gynecologic cancer research team.  [Read More]


March 18 - A Replication Stress Biomarker Correlates with Response to Gemcitabine Versus Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer

  • Panos Konstantinopoulos, MD, PhD

    Dana-Farber Cancer Institute

Panagiotis (Panos) A Konstantinopoulos, MD, PhD is Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an Associate Professor of Medicine at Harvard Medical School. His translational research career focuses on ovarian cancer and other gynecologic malignancies with an important niche in the areas of DNA Damage and Repair and Immunotherapy. His work has focused on unraveling mechanisms of resistance to chemotherapy and targeted agents, developing the rationale and preclinical data for novel drug combinations in ovarian cancer, and on identification of novel diagnostic and predictive biomarkers of therapeutic response in gynecologic cancers as well investigating their mechanistic implication in carcinogenesis.  [Read More]


Click on the Zoom icon below to join or CLICK HERE
If you are having trouble logging into the meeting, please feel to contact us by clicking on the contact us tab. 

For more information about this seminar series, email: dfhcc@partners.org or Kati Poulin.